title: UPDRS activity of daily living score as a marker of Parkinson's disease progression.
abstract: The activities of daily living (ADL) subscore of the Unified Parkinson's Disease Rating Scale (UPDRS) captures the impact of Parkinson's disease (PD) on daily function and may be less affected than other subsections by variability associated with drug cycle and motor fluctuations. We examined UPDRS mentation, ADL and motor subscores in 888 patients with idiopathic PD. Multiple linear regression analyses determined the association between disease duration and UPDRS subscores as a function of medication status at examination and in a subset of patients with multiple examinations. Independent of medication status and across cross-sectional and longitudinal analyses, ADL subscores showed a stronger and more stable association with disease duration than other UPDRS subscores after adjusting for age of disease onset. The association between disease duration and the motor subscore depended on medication status. The strong association between ADL subscore and disease duration in PD suggests that this measure may serve as a better marker of disease progression than signs and symptoms assessed in other UPDRS sections.
authors.affiliation: Department of Neurology, University of Virginia, Charlottesville, Virginia 22903, USA. mbh3y@virginia.edu
authors.forename: Madaline B
authors.initials: MB
authors.lastname: Harrison
authors.forename: Scott A
authors.initials: SA
authors.lastname: Wylie
authors.forename: Robert C
authors.initials: RC
authors.lastname: Frysinger
authors.forename: James T
authors.initials: JT
authors.lastname: Patrie
authors.forename: Diane S
authors.initials: DS
authors.lastname: Huss
authors.forename: Lillian J
authors.initials: LJ
authors.lastname: Currie
authors.forename: G Frederick
authors.initials: GF
authors.lastname: Wooten
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D011597:Psychomotor Performance; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa